Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose comparison study of conbercept for wet age-related macular degeneration with low vision
ChiCTR2000036525Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Oct 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in exudative macular degeneration (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Best corrected visual acuity. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2000036525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036525.